Chad Christine, MD
Professor
Neurology
School of Medicine

415-353-9046

Awards

Show all (6) Hide

  • Elected as Fellow of AAN, American Academy of Neurology (AAN), 2018
  • Elected as Fellow of the ANA, American Neurological Association (ANA), 2013
  • William Koller Memorial Fund Award, International Movement Disorder Society, 2006
  • Innovative Curricular Design and Program Development, UCSF Academy of Medical Educators, 2006
  • Kean-Haas Fellowship for International Study, Cornell University Medical College, 1991
  • Walton Foundation Scholarship, Stanford University School of Medicine, 1988

Education & Training

Show all (2) Hide

  • M.D. School of Medicine Cornell University Medical College 1991
  • BA Physics and English Cornell University 1985

Websites

Show all (1) Hide

Grants and Projects

Show all (11) Hide

  • PD 1104: An Observational, Long-Term Extension Study for Participants of Prior VY-AADC01 or VY-AADC02 Clinical Studies, Neurocrine Biosciences, Inc, 2018-2029
  • Open-Label Safety Study of Glial cell Line derived neurotrophic factor Gene transfer (AAV2-GDNF) in Parkinson’s disease, Brain Neurotherapy Bio, Inc, 2020-2026
  • PD 1105: A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson’s Disease Patients with Motor Fluctuations, Neurocrine Biosciences, Inc, 2018-2023
  • Relationship of B12 status measures with outcomes in SURE-PD2, SURE-PD3 and STEADY-PD III, Michael J Fox Foundation for Parkinson's Research, 2020-2022
  • NLY01-PD-1Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease, Neuraly, Inc, 2020-2021
  • PD 1102: An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion using a Posterior Trajectory into the Putamen of Participants with Parkinson’s Disease with fluctuating Responses to Levodopa., Voyager Therapeutics, 2017-2021
  • Relationship of cerebrospinal markers of B12 status to baseline status and outcomes in the DATATOP study, NIH and Michael J Fox Foundation for Parkinson's Research, 2016-2019
  • “A Phase 3 double-blind placebo-controlled parallel group study of isradipine as a disease modifying agent in patients with early Parkinson disease.”, NIH, 2014-2015
  • Parkinson's Disease Neuroprotection Clinical Trial, NIH, 2002-2015
  • The Relationship of Vitamin B12 status and Parkinson’s disease, Michael J Fox Foundation for Parkinson's Research, 2014-2015
  • Mechanisms Underlying Homosynaptic Long Term Depression, NIH, 1995-2000

Publications (60)

Top publication keywords:
Subthalamic NucleusAntiparkinson AgentsCarboxy-LyasesPutamenHomocysteineParkinson DiseaseParkinsonian DisordersLevodopaAromatic-L-Amino-Acid DecarboxylasesVitamin B 12Dopamine AgentsNarcolepsyGenetic TherapyAmphetamineDyskinesias

Show all (55 more) Hide